Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | SMARCB1 negative |
| Therapy | Fenretinide + Vorinostat |
| Indication/Tumor Type | rhabdoid cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| SMARCB1 negative | rhabdoid cancer | sensitive | Fenretinide + Vorinostat | Preclinical | Actionable | In a preclinical study, the combination of Zolinza (vorinostat) and fenretinide induced apoptosis and inhibited growth of rhabdoid tumor cell lines in culture (PMID: 23764045). | 23764045 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (23764045) | The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. | Full reference... |